Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer
JAMA Network Open · 29.03.2024 · 7 (3) · e244258
DOI: 10.1001/jamanetworkopen.2024.4258 ↗Kurz gefasst
Metaanalyse in der Zeitschrift JAMA Network Open, online erschienen am 29.03.2024. Verfasst von Arya Haj-Mirzaian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Evidence-Based Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Prostatic Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AHRQ HHS.
Abstract (Originalsprache)
Importance Multiple strategies integrating magnetic resonance imaging (MRI) and clinical data have been proposed to determine the need for a prostate biopsy in men with suspected clinically significant prostate cancer (csPCa) (Gleason score ≥3 + 4). However, inconsistencies across different strategies create challenges for drawing a definitive conclusion.
Objective
To determine the optimal prostate biopsy decision-making strategy for avoiding unnecessary biopsies and minimizing the risk of missing csPCa by combining MRI Prostate Imaging Reporting & Data System (PI-RADS) and clinical data. Data Sources PubMed, Ovid MEDLINE, Embase, Web of Science, and Cochrane Library from inception to July 1, 2022. Study Selection English-language studies that evaluated men with suspected but not confirmed csPCa who underwent MRI PI-RADS followed by prostate biopsy were included. Each study had proposed a biopsy plan by combining PI-RADS and clinical data. Data Extraction and Synthesis Studies were independently assessed for eligibility for inclusion. Quality of studies was appraised using the Quality Assessment of Diagnostic Accuracy Studies 2 tool and the Newcastle-Ottawa Scale. Mixed-effects meta-analyses and meta-regression models with multimodel inference were performed. Reporting of this study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Main Outcomes and Measures Independent risk factors of csPCa were determined by performing meta-regression between the rate of csPCa and PI-RADS and clinical parameters. Yields of different biopsy strategies were assessed by performing diagnostic meta-analysis.
Results
The analyses included 72 studies comprising 36 366 patients. Univariable meta-regression showed that PI-RADS 4 (β-coefficient [SE], 7.82 [3.85]; P = .045) and PI-RADS 5 (β-coefficient [SE], 23.18 [4.46]; P < .001) lesions, but not PI-RADS 3 lesions (β-coefficient [SE], −4.08 [3.06]; P = .19), were significantly associated with a higher risk of csPCa. When considered jointly in a multivariable model, prostate-specific antigen density (PSAD) was the only clinical variable significantly associated with csPCa (β-coefficient [SE], 15.50 [5.14]; P < .001) besides PI-RADS 5 (β-coefficient [SE], 9.19 [3.33]; P < .001). Avoiding biopsy in patients with lesions with PI-RADS category of 3 or less and PSAD less than 0.10 (vs <0.15) ng/mL 2 resulted in reducing 30% (vs 48%) of unnecessary biopsies (compared with performing biopsy in all suspected patients), with an estimated sensitivity of 97% (vs 95%) and number needed to harm of 17 (vs 15). Conclusions and Relevance These findings suggest that in patients with suspected csPCa, patient-tailored prostate biopsy decisions based on PI-RADS and PSAD could prevent unnecessary procedures while maintaining high sensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Evidence-Based Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
- Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Förderung
- AHRQ HHS
Zitieren
APA
Haj-Mirzaian, A., Burk, K. S., Lacson, R., Glazer, D. I., Saini, S., Kibel, A. S., & Khorasani, R. (2024). Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer. JAMA Network Open, 7(3), e244258. https://doi.org/10.1001/jamanetworkopen.2024.4258
Vancouver
Haj-Mirzaian A, Burk KS, Lacson R, Glazer DI, Saini S, Kibel AS, et al. Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer. JAMA Network Open. 2024;7(3):e244258. doi:10.1001/jamanetworkopen.2024.4258
BibTeX
@article{HajMirzaian2024,
author = {Haj-Mirzaian, Arya and Burk, Kristine S and Lacson, Ronilda and Glazer, Daniel I and Saini, Sanjay and Kibel, Adam S and Khorasani, Ramin},
title = {Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {3},
pages = {e244258},
doi = {10.1001/jamanetworkopen.2024.4258}
}
EUVIMED